MedPath

Effects of repetitive transcranial magnetic stimulation to supplementary motor area and primary motor cortex on motor performances in people with Parkinson disease

Phase 2
Conditions
The participant in this study is people with Parkinson disease.
Brain stimulation
Bradykinesia
Coordination
Parkinson disease
Reach-to-grasp performance
Registration Number
TCTR20230118001
Lead Sponsor
Research Grant for New Scholar supported by National Research Council of Thailand (NRCT)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
40
Inclusion Criteria

1 age range from 40 to 80 years
2 mild to moderate severity with Hoehn and Yahr H&Y stages 1 to 3
3 more impaired on the right hand dominant as examined by the Unified Parkinson Disease Rating Scale part III
4 On medication during practicing and testing in this study
5 ability to understand and follow simple commands with greater than 23 on the Mini mental state examination Thai version 2002
6 Have normal or corrected to normal vision and normal hearing and
7 ability to sit independently for more than one hour

Exclusion Criteria

1.contraindication for TMS confirmed by TMS screening questionnaire
2.severe action or resting tremor
3. severe rigidity
4. ON/OFF medication fluctuations
5. severe disability from dyskinesia
6. Diagnosed with secondary parkinsonism
7. other neurological and/or musculoskeletal problems
8.implanted deep brain stimulation (DBS) or plan to have DBS during the study period

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Behavioral outcomes Baseline and post intervention The Behavioral outcomes will be represented by reach-to-grasp actions that will be measured by the motion monitor tracking systems. This will be showed by the kinematic data such as movement time(ms).
Secondary Outcome Measures
NameTimeMethod
Cortical outcomes Baseline and Post intervention Cortical outcomes will be represented by corticomotor excitability (MEP) and cortical inhibition (CSP) that will be measured by a single-pulse TMS.
© Copyright 2025. All Rights Reserved by MedPath